Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
bilateral miliary changes. Five years previously his daughters had both been treated for isoniazid and ethambutol resistant TB and he had received TB preventive therapy with rifampicin. Computed tomography scanning showed diffuse bilateral tiny nodules in the lungs, enlarged mediastinal, hilar and abdominal lymph nodes with splenomegaly. He subsequently developed headache and complex partial seizures. Lumbar puncture and MRI brain were normal. Early diagnostics on induced sputum were inconclusive. Staining tests were nonconcordant and the direct PCR test detected MTB DNA but not to a reportable amplification level. This led to a clinical decision to pursue further tissue sampling. Endobronchial ultrasound and mediastinal lymph node biopsy showed histology typical of sarcoidosis with poorly defined, non-caseating granulomas and foci of dystrophic calcification. Tissue staining for mycobacteria and fungi was negative. A serum ACE level was markedly elevated at 264 U/L. Seizures remained controlled on levetiracetam, his cough improved and the clinical syndrome remitted without steroids. 

Key learning points drawn from this case include: the diagnostic overlap between tuberculosis and sarcoidosis both clinically and histopathologically, pitfalls of TB PCR testing and choice of empirical and preventive therapy options for potential multi-drug resistant TB.

doi: 10.1016/j.clinpr.2022.100176

16 An unusual pathogen in post-operative discitis
Lilly Tian¹
NHS Tayside, Dundee, United Kingdom
* Corresponding author.

Abstract

* Bacillus cereus* is an organism most commonly associated with self-limiting gastroenteritis, however increasingly recognised as a rare but important cause of extra-gastrointestinal infection. The ubiquitous nature of this environmental organism, alongside its spore forming ability, means it has the potential to survive in healthcare settings where it may be a source of nosocomial infection. This case demonstrates the role of *B. cereus* as an unusual pathogen in post-operative discitis, in a young, healthy, immunocompetent individual. A 25 year old gentleman who had recently undergone L4/5 decompression and microsurgery presented 3 weeks later with cauda equina syndrome, with MRI suggestive of an infected extradural collection and L4/5 discitis. Subsequent redo L4/5 discectomy and wound washout isolated *B. cereus* from 3 of 6 theatre samples. IV Vancomycin was administered before rationalising to IV Teicoplanin to complete a 6 week course, with post-treatment culture of this organism being often cultivable and due to the ubiquity of *B. cereus* in the environment, culture of this organism is often considered as questionable clinical relevance. Whilst the significance of *B. cereus* will vary on a case-to-case basis, this case echoes an evolving literature base demonstrating the spectrum of infection it may cause, as well as a potentially underestimated role in post-operative infection. Given the common resistance of *B. cereus* to penicillins and beta lactams, an awareness of this organism is of particular importance given it may not be covered by empirical antibiotic regimens.

doi: 10.1016/j.clinpr.2022.100177

17 COVID-19 vaccine hesitancy among a UK cohort of patients living with HIV
Huw Lewis¹, Julia Greig¹, James Meiring³
¹Sheffield Teaching Hospitals, Sheffield, United Kingdom
²University of Sheffield, Sheffield, United Kingdom
* Corresponding author.

Abstract

Introduction: There is evidence that people living with HIV (PLWH) have a higher risk of death and hospitalisation from COVID-19, particularly those with low CD4 counts or detectable viraemia. There have been calls to prioritise vaccination for PLWH globally, with early access to vaccination available in the UK.

Methods: We performed a retrospective review of 200 sequential patients booked into HIV clinic within Sheffield Teaching Hospitals between November 2021 and January 2022 collecting HIV treatment and vaccination uptake (VU) data.

Result: In this cohort of PLWH, triple VU by age closely matched national vaccination rates (89% in the 60-64 age group vs 84% nationally and 42% vs 43% in the 30-39 age group). Within the cohort there was no significant difference in VU between ethnic groups (white 89%, black 90%, asian 100% (p = 0.57)). There was a significant difference in VU in those with detectable viraemia, with 42% having received ≥3 vaccinations, compared with 69% in the undetectable group (p = 0.016). There was a similar difference for those with known treatment adherence issues (50% vs 70% (p = 0.002)).

Discussion: To our knowledge, this is the first study looking at COVID-19 vaccine uptake amongst PLWH within the UK. We identified patients most at risk of severe outcomes from COVID-19, are the least likely to be fully vaccinated. The same methods used to engage patients with anti-retroviral treatment is likely to be of benefit in increasing VU. Understanding the reasons for both poor adherence and poor VU would enable improved healthcare engagement with this population.

doi: 10.1016/j.clinpr.2022.100179